Lionbridge Technologies Inc. (Nasdaq:LIOX) will announce financial results for the fourth quarter and fiscal year ended December 31, 2010 on Tuesday morning, February 8th, 2011. Lionbridge management will conduct a conference call at 9:00 a.m. (Eastern) on February 8th to discuss financial performance for the quarter. To participate, callers within the United States can dial 800-857-9821 and international callers can dial 210-234-0023.
Lionbridge Technologies, Inc. provides language, development, and testing services. Its Global Language and Content segment provides product localization services.
National Health Partners, Inc. (OTCBB:NHPR) has achieved positive earnings for the quarter ended September 30, 2010 compared to a loss of $522,542 for the same period last year. Revenues for the 3rd quarter grew 12.3% over the same period last year. National Health Partners attributes the net earnings to the significant cost-cutting initiatives taken over the past couple of quarters and which is continuing in the 4th quarter.
Have you found that access to affordable medical in the United States is an entitlement? Yet dependant upon a seemingly arbitrary matrix of things, and the government insurance packages which are available for the elderly, the permanently disabled, people who have failing kidneys, the actual impoverished and children from low-income individuals. But how poor must one be to be eligible varies from state to state and also from year to year. Workers at most of the large firms and many of hte small firms have been able to take advantage of group insurance plans negotiated by way of their employers. Although millions of people who are employed in low-paying service, retail or perhaps contracting jobs need to seek individual insurance plans, which may be unaffordable or maybe unavailable because of their healthcare histories. Others obtain insurance with insurance deductibles so high or insurance coverage limits so low that one bad crash or illness would lead them close to bankrupt. The need for affordable healthcare alternatives has never been greater.
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called “CARExpress.” CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna.
Unilife Corporation (Nasdaq:UNIS) announced that it intends to release its financial results for the fiscal 2011 second quarter ended December 31, 2010 aftermarket trading ends on Monday, February 14, 2011. Management has scheduled a conference call for 4:30 p.m. U.S. Eastern Standard Time on February 14, 2011 (Tuesday, February 15 at 8:30 a.m. AEDT), to review the Company's financial results, market trends, and future outlook. The conference call will be broadcast over the Internet as a "live" listen only webcast. To listen, please go to: ir.unilife.com/events.cfm. Listeners are urged to login approximately 20 minutes before the conference call is scheduled to begin in order to register, as well as download and install any necessary audio software.
Unilife Corporation, a medical device company, focuses on the design, development, manufacture, and supply of a proprietary range of retractable syringes in the United States and internationally.
PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).
Alzheimer's disease has no existing cure, and yet treatment options designed for symptoms can be purchased and research carries on. Despite the fact that most current Alzheimer treatments can't cease Alzheimer's disease from moving on, they can in the short term gradual the deterioration involving signs of illness in addition to strengthen well being for anyone with Alzheimer's disease as well as those caregivers. Right now, there exists a international effort under route to finding possible ways to manage the ailment, postponement its beginning, and stop it from evolving.
The NuroPro Blood Test is PWRM’s diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease .
PWRM’s BC-SeraPro(NYSE:TM) is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to PWRM’s patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis. Probability score is ranged from 0.0 to 1.0. Results of PWRM’s BC-SeraPro(TM) test should not be considered a stand alone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrig’s disease), Alzheimer’s, Parkinson’s diseases, breast cancer, and drug resistance.
PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD), Parkinson’s disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA.
Abraxas Petroleum Corp. (Nasdaq:AXAS) announced completion of its first Eagle Ford well in South Texas and presentation details for the upcoming IPAA OGIS conference. In DeWitt County, Texas, Blue Eagle Energy, LLC, the previously announced joint venture between Abraxas and Rock Oil Company, LLC, drilled the T Bird 1H to a total measured depth of 19,450 feet, including a 5,700 foot lateral which is one of the longest laterals drilled in the Eagle Ford Shale play to-date. The well was completed with 15-stage fracture stimulation and recently placed on-line at a restricted rate approximately 75 days after spud.
Abraxas Petroleum Corporation, an independent energy company, engages in the acquisition, development, exploration, and production of oil and gas primarily in the Rocky Mountain, Mid-Continent, Permian Basin, and Gulf Coast regions of the United States.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM). Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates receiving 3,000,000 shares of (144) restricted common stock from the company, as well as 3,000,000 shares of free trading shares from a third party for six months of advertisement services for National Health Partners Inc. (OTC:NHPR).